IQ-AI Ltd - Jersey-based medical services firm - Says subsidiary Imaging Biometrics LLC's two new pre-clinical studies show oral Gallium Maltolate inhibits brain tumour growth in children. Says the results are consistent with previous work conducted in the Schmainda Lab at the Medical College of Wisconsin. This follows IB's application for Orphan Drug Designation to the US Food & Drug Administration back in April for the use of GaM in pediatric brain tumours. Notes application is currently under review.
Current stock price: 2.81 pence, up 3.9%
12-month change: down 20%
By Sabrina Penty, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Iq-ai Ltd (IQAI)